ABBOTT’S New Device to Treat A-Fib Patients
Abbott’s Amplatzer Amulet Device
Amulet is the first and only minimally invasive treatment option to offer immediate closure of the left atrial appendage (LAA)
Approved by the FDA to Treat People with Atrial Fibrillation At Risk of Stroke, the Amulet’s option closes off the left atrial appendage so blood thinners are no longer needed following implantation, (unlike the Watchman). The Abbott’s New Device to Treat A-Fib Patients helps to prevent blood clots from forming and leaving the LAA, reducing risk of stroke to patients with Atrial Fibrillation, the most common persistent cardiac arrhythmia.
The press release is dated August 16, 2021, when it was announced that the U.S. Food and Drug Administration (FDA) approved the company’s Amplatzer Amulet Left atrial appendage occluder to treat people with A-Fib.
LAA is a Small Pouch to the Upper Left Chamber of the Heart
The LAA is a small pouch connected to the upper left chamber of the heart.
For people with AFib, the most common of the persistent arrhythmia s, or irregular heartbeats is the heart’s ability to effectively pump blood can be disrupted, allowing blood to pool and collect in the LAA causing an increased risk for clotting. If clots reach the blood stream, they can travel to the brain and cause a stroke.
For patients with AFib who are unable to take blood-thinning medication long term, physicians may opt for occlusion (or closure) of the LAA through a minimally invasive procedure using devices like Abbott’s Amulet to seal off the LAA entirely and reduce the risk of stroke.
As The World’s Population Ages
A Surge In Atrial Fibrillation Cases is Upon Us
“As the world’s population continues to age, we’re seeing a surge in atrial fibrillation cases, and with that comes increased risk of stroke”,said Dhanunjaya Lakkireddy, M.D., Kansas City Heart Rhythm Institute at HCA Midwest Health, who served as principal investigator for the study that led to FDA approval.
“The approval of Abbott’s Amulet device provides physicians with a treatment option that reduces the risk of stroke and eliminates the need for blood-thinning medication immediately after the procedure, which is incredibly valuable given the bleeding risks associated with these medicines.”
In Reference to “The Watchman”
The First LAA Closur Procedure for A-Fib Patients
Before this approval, the only minimally invasive option for LAA occlusion for U.S. physicians and their patients was a solution with a single component to seal the LAA that requires blood-thinning drugs to heal and additional patient monitoring to ensure closure.
In contrast, Abbot’s Amulet uses dual-seal technology to completely and immediately seal off the LAA. Amulet recipients don’t need to use blood thinning medication following the procedure.
Additionally, the device can treat a broad range of anatomies and has the widest range of occluder sizes on the market; it is also recapturable and repositionable to ensure optimal placement. ABBOTT’S New Device to Treat A-Fib Patients can get you off of blood thinners for life!
Amulet’s Unique Dual-Seal Approach
“Amulet’s Approach Has Made it The Number One LAA Closure Product in Europe”
Today’s device approval by the FDA is an important milestone in allowing us to bring this treatment option to American physicians and patients,” said Michael Dale, senior vice president of Abbott’s structural heart business.
“Consistent with our mission purpose, our minimally invasive Amulet procedure for reducing stroke risk in patients with atrial fibrillation will help people live better lives through better health.”
About Amplatzer Amulet
The Amplatzer Amulet LAA Occluder has been approved for use in more than 80 countries, including in Europe, Canada and Australia, since its initial CE Mark approval in 2013. The FDA approval is supported by findings from the Amulet IDE trial, a large-scale randomized head-to-head study comparing Amulet with an alternative minimally invasive LAA occlusion device, which will be virtually presented at the European Society of Cardiology (ESC) 2021, Congress on August 30, 2021,.
For U.S. important safety information on Amulet, visit: https://abbo.tt/AmuletISI.
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.
I‘d like to invite you to my post I published on “The Watchman” as the two Products and options are very similar.
Abbott Amulet Option
Abbot’s Amulet uses dual-seal technology to completely and immediately seal off the LAA. Amulet recipients don’t need to use blood thinning medication following the procedure.
The Watchman Implant fits right into your LAA. It’s designed to permanently close it off and keep those blood clots from escaping.
Comparing the difference of the two is very important if you’re thinking about one of these procedures being done. Personally, I am considering it myself, thus the research on both procedures. I like the Amulet Option, because not only do they dual-seal the LAA completely and immediately, but the fact that they are number one is a deal breaker opposed to the Watchman.
I’m still researching the Abbott company and it’s technology with health care. I’ve signed up to their newsletter to stay on top of the newest procedures available to consumers with Atrial Fibrillation. The Amplatzer Amulet has been a great find and discovery.
Take care and thanks for stopping in. If you’d like to read more on Atrial Fibrillation, scroll down on this page toward the bottom, you’ll see more posts.
Wishing you well,